Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBIT (2016 - 2025)

Historic EBIT for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $4.4 million.

  • Akebia Therapeutics' EBIT rose 13557.78% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year increase of 15100.31%. This contributed to the annual value of -$50.5 million for FY2024, which is 911.45% down from last year.
  • Latest data reveals that Akebia Therapeutics reported EBIT of $4.4 million as of Q3 2025, which was up 13557.78% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' EBIT registered a high of $34.1 million during Q2 2022, and its lowest value of -$79.3 million during Q2 2021.
  • For the 5-year period, Akebia Therapeutics' EBIT averaged around -$21.6 million, with its median value being -$13.0 million (2023).
  • In the last 5 years, Akebia Therapeutics' EBIT tumbled by 114126.64% in 2024 and then soared by 26147.85% in 2025.
  • Over the past 5 years, Akebia Therapeutics' EBIT (Quarter) stood at -$65.3 million in 2021, then skyrocketed by 92.55% to -$4.9 million in 2022, then surged by 128.22% to $1.4 million in 2023, then plummeted by 1141.27% to -$14.3 million in 2024, then skyrocketed by 131.1% to $4.4 million in 2025.
  • Its EBIT was $4.4 million in Q3 2025, compared to $14.1 million in Q2 2025 and $13.5 million in Q1 2025.